SM2 The Consequences of Greater Net Price Transparency for Innovative Medicines in Europe: Insights from a Multi-Agent Simulation Model

Abstract

Authors

W. Van Dyck M. Riccaboni T. Swoboda M. Pistollato

Full Text Cite This Article
Back to Volume 24, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×